Global Rivaroxaban Market to Surpass US$ 7.0 Billion by 2026 – Coherent Market Insights


SEATTLE, July 18, 2018 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, the global rivaroxaban market was valued at US$ 5,653 in 2017 and is projected to exhibit a CAGR of 1.5% over the forecast period (2018 – 2026) on account patent expiry during the forecast period, expected to reduce the product price then.

Request Sample Copy of this Report

Key Trends and Analysis of the Rivaroxaban Market:

Increasing research and development activities by manufacturers, universities, and hospitals to expand the clinical application of rivaroxaban is expected to fuel the rivaroxaban market growth over the forecast period. For instance, the University Hospital Inselspital, Berne, Bayer, Janssen, and two others are working in collaboration to investigate the efficacy of rivaroxaban in patients undergoing bariatric surgery and the trial was under phase II as of May 2018.

However, high treatment cost using rivaroxaban is one of the major factors that might hinder the market growth. Therefore, market players are providing facilities such as Xarelto manufacturer coupon or patient assistance program to reduce the out-of-pocket cost of patients. Furthermore, patent expiration of branded rivaroxaban, Xarelto, in 2020, provides opportunity for the new entrants to invade the market with generic version of the drug at lower cost, which is also expected to hinder the market growth.

To know the latest trends and insights prevalent in this market, click the link below:

https://www.coherentmarketinsights.com/market-insight/rivaroxaban-market-1962

Key Market Takeaways:

  • Rivaroxaban market is projected to witness a CAGR of -3.1% during the forecast period (2018–2026), owing to increasing market penetration
  • Increasing research activities to expand clinical application of the drug is expected to propel the demand for rivaroxaban, in turn boosting the global rivaroxaban market growth
  • Major players operating in the global rivaroxaban market include Bayer Ag and Janssen Pharmaceuticals, Inc.

Single User License: $4500

Click Here to buy this report now

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave. 
#3200 
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com